Using electronic tools to track side effects in cancer patients receiving CAR T therapy
ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy: Feasibility Study (CARTePRO)
This study is testing if using digital tools can help cancer patients on CAR T therapy report side effects more easily and improve their treatment experience.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 11 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stiftung Swiss Tumor Institute Academic / other |
| Drugs / interventions | CAR T |
| Locations | 1 site (Zürich) |
| Trial ID | NCT05354973 on ClinicalTrials.gov |
What this trial studies
This observational study aims to implement electronic Patient Reported Outcomes (ePRO) to monitor and manage side effects in patients undergoing CAR T-cell therapy for hematological malignancies. By utilizing digital tools, the study seeks to enhance the reporting of adverse events and improve the safety and accessibility of CAR T treatment. The feasibility of engaging patients through ePRO assessments will be evaluated to determine their effectiveness in real-time toxicity management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are receiving CAR T-cell treatment and have access to a personal smartphone.
Not a fit: Patients with mental health issues, physical limitations, or insufficient smartphone knowledge may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved safety and better management of side effects for cancer patients undergoing CAR T therapy.
How similar studies have performed: While the use of ePRO tools in clinical settings is gaining traction, this specific application in CAR T therapy is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed ICF 2. Patients \> 18 years 3. Patients receiving CAR T cell treatment 4. Personal smartphone with iOS or Android system. The operating system must be updated to one of the two newest main versions. Exclusion Criteria: 1. Patients, whose compliance to the studies' protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted. 2. Patients with insufficient knowledge about the use of a smartphone.
Where this trial is running
Zürich
- Klinik für Hämatologie und Onkologie — Zürich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Panagiotis Samaras, PD.Dr.med — Klinik für Hämatologie und Onkologie
- Study coordinator: Andreas Trojan, Prof.Dr.med
- Email: trojan@1st.ch
- Phone: +41 76 343 02 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.